-
Something wrong with this record ?
Acute effects of glucocorticoids on serum markers of osteoclasts, osteoblasts, and osteocytes
K. Brabnikova Maresova, K. Pavelka, JJ. Stepan,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
ProQuest Central
from 2002-01-01 to 1 year ago
Medline Complete (EBSCOhost)
from 2000-01-01 to 1 year ago
Nursing & Allied Health Database (ProQuest)
from 2002-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 2002-01-01 to 1 year ago
- MeSH
- Biomarkers blood MeSH
- C-Reactive Protein metabolism MeSH
- Adult MeSH
- Genetic Markers MeSH
- Glucocorticoids pharmacology therapeutic use MeSH
- Collagen Type I blood MeSH
- Bone Morphogenetic Proteins blood MeSH
- Middle Aged MeSH
- Humans MeSH
- RANK Ligand blood MeSH
- Intercellular Signaling Peptides and Proteins blood MeSH
- Osteoblasts drug effects metabolism MeSH
- Osteocytes drug effects metabolism MeSH
- Osteocalcin blood MeSH
- Osteoclasts drug effects metabolism MeSH
- Osteoprotegerin blood MeSH
- Peptide Fragments blood MeSH
- Peptides blood MeSH
- Procollagen blood MeSH
- Prospective Studies MeSH
- Rheumatic Diseases blood drug therapy pathology MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Case-Control Studies MeSH
- Dose-Response Relationship, Drug MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
The aim of this study was to investigate the acute effects of oral glucocorticoids in doses used in clinical practice on biochemical indices of the function of osteoclasts, osteoblasts, and osteocytes. In 17 adult patients suffering from various medical pathologies requiring systemic steroid therapy that were never before treated with glucocorticoids, glucocorticoid treatment was initiated (mean prednisolone equivalent dose of 23.1 ± 12.7 mg/day, range 10-50). Fasting morning serum concentrations of osteocalcin (OC), amino-terminal propeptide of type I procollagen (PINP), type 1 collagen cross-linked C-telopeptide (βCTX), soluble receptor activator of nuclear factor kappaB ligand (sRANKL), osteoprotegerin (OPG), sclerostin, Dickkopf-1 (Dkk-1), and high-sensitivity C-reactive protein (hsCRP) were measured at baseline and on three consecutive days. Significant reductions in serum OC, PINP, OPG, sclerostin, and hsCRP were observed during 96 h of glucocorticoid administration, while serum βCTX showed a significant percentual increase. A significant positive correlation was found between serum concentrations of Dkk-1 and βCTX after 96 h of treatment with glucocorticoids. A significant drop in serum sclerostin, OPG, and OC observed in this study may reflect the rapid glucocorticoid-induced apoptosis of osteocytes.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13031765
- 003
- CZ-PrNML
- 005
- 20131003104736.0
- 007
- ta
- 008
- 131002s2013 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00223-012-9684-4 $2 doi
- 035 __
- $a (PubMed)23247536
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Brabnikova Maresova, Kristyna $u Institute of Rheumatology, Prague, Czech Republic.
- 245 10
- $a Acute effects of glucocorticoids on serum markers of osteoclasts, osteoblasts, and osteocytes / $c K. Brabnikova Maresova, K. Pavelka, JJ. Stepan,
- 520 9_
- $a The aim of this study was to investigate the acute effects of oral glucocorticoids in doses used in clinical practice on biochemical indices of the function of osteoclasts, osteoblasts, and osteocytes. In 17 adult patients suffering from various medical pathologies requiring systemic steroid therapy that were never before treated with glucocorticoids, glucocorticoid treatment was initiated (mean prednisolone equivalent dose of 23.1 ± 12.7 mg/day, range 10-50). Fasting morning serum concentrations of osteocalcin (OC), amino-terminal propeptide of type I procollagen (PINP), type 1 collagen cross-linked C-telopeptide (βCTX), soluble receptor activator of nuclear factor kappaB ligand (sRANKL), osteoprotegerin (OPG), sclerostin, Dickkopf-1 (Dkk-1), and high-sensitivity C-reactive protein (hsCRP) were measured at baseline and on three consecutive days. Significant reductions in serum OC, PINP, OPG, sclerostin, and hsCRP were observed during 96 h of glucocorticoid administration, while serum βCTX showed a significant percentual increase. A significant positive correlation was found between serum concentrations of Dkk-1 and βCTX after 96 h of treatment with glucocorticoids. A significant drop in serum sclerostin, OPG, and OC observed in this study may reflect the rapid glucocorticoid-induced apoptosis of osteocytes.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a biologické markery $x krev $7 D015415
- 650 _2
- $a kostní morfogenetické proteiny $x krev $7 D019485
- 650 _2
- $a C-reaktivní protein $x metabolismus $7 D002097
- 650 _2
- $a studie případů a kontrol $7 D016022
- 650 _2
- $a kolagen typu I $x krev $7 D024042
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a genetické markery $7 D005819
- 650 _2
- $a glukokortikoidy $x farmakologie $x terapeutické užití $7 D005938
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mezibuněčné signální peptidy a proteiny $x krev $7 D036341
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a osteoblasty $x účinky léků $x metabolismus $7 D010006
- 650 _2
- $a osteokalcin $x krev $7 D015675
- 650 _2
- $a osteoklasty $x účinky léků $x metabolismus $7 D010010
- 650 _2
- $a osteocyty $x účinky léků $x metabolismus $7 D010011
- 650 _2
- $a osteoprotegerin $x krev $7 D053244
- 650 _2
- $a peptidové fragmenty $x krev $7 D010446
- 650 _2
- $a peptidy $x krev $7 D010455
- 650 _2
- $a prokolagen $x krev $7 D011347
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a ligand RANK $x krev $7 D053245
- 650 _2
- $a revmatické nemoci $x krev $x farmakoterapie $x patologie $7 D012216
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Pavelka, Karel $u -
- 700 1_
- $a Stepan, Jan J $u -
- 773 0_
- $w MED00000994 $t Calcified tissue international $x 1432-0827 $g Roč. 92, č. 4 (2013), s. 354-61
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/23247536 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20131002 $b ABA008
- 991 __
- $a 20131003105254 $b ABA008
- 999 __
- $a ok $b bmc $g 995852 $s 830210
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 92 $c 4 $d 354-61 $i 1432-0827 $m Calcified tissue international $n Calcif Tissue Int $x MED00000994
- LZP __
- $a Pubmed-20131002